Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALADE: Choline Alfoscerate in Degenerative Mild Cognitive Impairment
NCT05041790Phase 4Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of choline alfoscerate in Mild Cognitive Impairment (MCI), sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
choline alfoscerate
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05041790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041790.